Effects of selenium on peripheral blood mononuclear cell membrane fluidity, interleukin-2 production and interleukin-2 receptor expression in patients with chronic hepatitis

Table 1 Influence of selenium on IL-2 and IL-2R expression (mean ± SD)

Groups	Cases	IL-2 activation(1 × 103 U/L)	IL-2R expression(%)
Normal control group	10	72.96 ± 11.36	60.58 ± 10.56
+ tBHP	10	42.12 ± 12.06b	37.05 ± 8.06b
+ Selenium + tBHP	10	53.26 ± 18.15a	52.12 ± 9.68a
Patient control group	22	40.26 ± 9.55b	31.05 ± 5.09b
Patients + selenium	23	60.32 ± 15.24c	54.06 ± 5.22c

^bP < 0.01 vs normal control group;

^aP < 0.05 vs tBHP inducing damage group;

^cP < 0.05 vs patient control group.

Table 2 Influence of selenium on PBMC membrane fluidity (mean ± SD)

Groups	Cases	R	MDA (μmol/L)
Normal control group	10	0.14 ± 0.01	0.93 ± 0.08
+ tBHP	10	0.19 ± 0.02b	2.32 ± 0.25b
+ Selenium + tBHP	10	0.16 ± 0.02a	1.36 ± 0.09a
Patient control group	22	0.17 ± 0.01b	1.44 ± 0.08b
Patients + selenium	23	0.15 ± 0.01c	1.21 ± 0.09c

^bP < 0.01 vs normal control group;

^aP < 0.05 vs tBHP inducing damage group;

^cP < 0.05 vs patient control group.

Table 3 IL-2 and IL-2R expression in PBMCs of patients before and after selenium treatment (mean ± SD)

Groups	Cases	IL-2 activation (1 × 103U/L)	IL-2R expression (%)
Before treatment
Normal control group	22	43.22 ± 9.25	31.24 ± 5.20
Selenium treated group	23	42.26 ± 9.55	31.05 ± 5.09
After treatment
Normal control group	18	49.45 ± 15.25	35.12 ± 6.49
Selenium treated group	17	60.32 ± 13.28a	46.05 ± 4.46b

^bP < 0.01 vs before treatment.

Table 4 Effect on PBMC membrane fluidity of patients before and after selenium treatment (mean ± SD)

Groups	Cases	R	Lipid peroxide (nmol/L)
Before treatment
Normal control group	22	0.17 ± 0.01	7.36 ± 4.15
Selenium treated group	23	0.17 ± 0.01	7.36 ± 4.08
After treatment
Normal control group	18	0.16 ± 0.01	6.15 ± 3.85
Selenium treated group	17	0.15 ± 0.01b	5.02 ± 2.50b

^bP < 0.01 vs before treatment.